From: Chondrocyte activity is increased in psoriatic arthritis and axial spondyloarthritis
axSpA | PsA | |||||||
---|---|---|---|---|---|---|---|---|
Total (n = 110) | Treatment-naïve (n = 34) | Currently treated, total (n = 63) | Previously treated (n = 13) | Total (n = 101) | Treatment-naïve (n = 13) | Currently treated, total (n = 76) | Previously treated (n = 12) | |
Age | ns | ns | ns | ns | ns | r = −0.55 | ns | ns |
p = −0.051 | ||||||||
BMI | ns | ns | ns | ns | ns | r = 0.60 | ns | ns |
p = 0.032 | ||||||||
Disease duration | ns | ns | ns | r = 0.54 | ns | r = 0.55 | ns | ns |
p = 0.030 | p = 0.052 | |||||||
ASDAS | ns | r = 0.45 | ns | ns | ns | ns | ns | ns |
p = 0.008 | ||||||||
HAQ | ns | ns | r = 0.47 | ns | r = −0.34 | ns | r = −0.35 | ns |
p = 0.010 | p = 0.004 | p = 0.008 | ||||||
Sex | ns | ns | ns | ns | ns | ns | ns | ns |
BASDAI | ns | ns | ns | ns | ns | ns | ns | ns |
BASFI | ns | ns | r = −0.30 | ns | ns | ns | ns | ns |
p = 0.008 | ||||||||
SJC68 | ns | ns | ns | ns | ns | ns | ns | r = −0.92 |
p = 0.0001 | ||||||||
TJC68 | ns | ns | ns | ns | ns | ns | ns | r = −0.89 |
p = 0.0003 |